Study drug QTX3034 for patients with KRAS G12D solid tumors (QTX3034-001) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to see if the study drug, QTX3034, either with or without cetuximab, is safe and effective for treating KRAS G12D mutated cancer. We are also trying to find the best dose of QTX3034 to use.
¿Cuál es la Condición que se está estudiando?
Solid Tumors with KRAS G12D Mutation
¿Quién puede participar en el Estudio?
Adults with solid tumors that:
- Are locally advanced or metastatic
- Contain a KRAS G12D mutation
- Have worsened following at least 1 line of standard therapy
For more information about this study, please contact the study team at 919-668-1861.
Grupo etario
Adultos
¿Qué Implica?
Si elige unirse a este estudio, podrá:
- Take the study drug, QTX3034, by mouth twice every day
- Depending on which group you are assigned to, you may also get IV infusions of cetuximab once every week
- Hágase biopsia del tumor
- Give blood and urine samples
- Realice tomografías computarizadas o resonancias magnéticas de manera regular.
Detalles del Estudio
Título Completo
[QTX3034-001] A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation
Investigador Principal
John H. Strickler, MD
Especialista en oncología médica
Número de Protocolo
IRB:
PRO00114908
NCT:
NCT06227377
Fase
Fase I
ClinicalTrials.gov
Ver en ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu